These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC; Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498 [TBL] [Abstract][Full Text] [Related]
7. Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel. Galeazzi R; Olivieri F; Spazzafumo L; Rose G; Montesanto A; Giovagnetti S; Cecchini S; Malatesta G; Di Pillo R; Antonicelli R Drugs Aging; 2018 Jul; 35(7):649-656. PubMed ID: 29936693 [TBL] [Abstract][Full Text] [Related]
8. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. AlMukdad S; Elewa H; Al-Badriyeh D J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168 [TBL] [Abstract][Full Text] [Related]
9. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100 [TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811 [TBL] [Abstract][Full Text] [Related]
11. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention. Johnson SG; Gruntowicz D; Chua T; Morlock RJ J Manag Care Spec Pharm; 2015 Jul; 21(7):552-7. PubMed ID: 26108379 [TBL] [Abstract][Full Text] [Related]
12. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors. Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954 [TBL] [Abstract][Full Text] [Related]
14. Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting. Stimpfle F; Karathanos A; Droppa M; Metzger J; Rath D; Müller K; Tavlaki E; Schäffeler E; Winter S; Schwab M; Gawaz M; Geisler T Thromb Res; 2014 Jul; 134(1):105-10. PubMed ID: 24856643 [TBL] [Abstract][Full Text] [Related]
15. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303 [TBL] [Abstract][Full Text] [Related]
16. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648 [TBL] [Abstract][Full Text] [Related]
17. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608 [TBL] [Abstract][Full Text] [Related]
18. Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre trial (NCT01930773). Kołtowski Ł; Aradi D; Huczek Z; Tomaniak M; Sibbing D; Filipiak KJ; Kochman J; Balsam P; Opolski G Kardiol Pol; 2016; 74(4):372-9. PubMed ID: 26365936 [TBL] [Abstract][Full Text] [Related]
19. Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention. Saiz-Rodríguez M; Belmonte C; Caniego JL; Koller D; Zubiaur P; Bárcena E; Romero-Palacián D; Eugene AR; Ochoa D; Abad-Santos F Clin Ther; 2019 Jun; 41(6):1199-1212.e2. PubMed ID: 31128980 [TBL] [Abstract][Full Text] [Related]
20. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials. Kheiri B; Osman M; Abdalla A; Haykal T; Pandrangi PV; Chahine A; Ahmed S; Osman K; Bachuwa G; Hassan M; Bhatt DL Catheter Cardiovasc Interv; 2019 Jun; 93(7):1246-1252. PubMed ID: 30403317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]